Company Description
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States.
It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.
It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib.
The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jan 26, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Dr. Zhengbin Yao Ph.D. |
Contact Details
Address: 18 Campus Blvd., Suite 100 Newtown Square, Pennsylvania 19073-3269 United States | |
| Phone | 240-780-6356 |
| Website | arrivent.com |
Stock Details
| Ticker Symbol | AVBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001868279 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President and Chief Executive Officer |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research and Development and Director |
| Robin LaChapelle M.A. | Co-Founder and Chief Operating Officer |
| Winston Kung M.B.A. | Chief Financial Officer and Treasurer |
| Yang Wang Ph.D. | Chief Technology Officer |
| James Paul Kastenmayer J.D., Ph.D. | General Counsel and Secretary |
| Dr. Dandan Dong | Chief Business Officer |
| Meghna Chowdary | Senior Vice President of Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | 8-K | Current Report |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| Apr 22, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 5, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Feb 2, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 30, 2024 | 8-K | Current Report |